3-[2-[(2S)-2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]propanoic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 3-[2-[(2S)-2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]propanoic acid
• 化学式: C₁₅H₂₃NO₄
• 分子量: 281.35
• InChiKey: GPJPFTGUNQODPS-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  20
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  78.8
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• US6197817B1
  申请人：——

  公开号：US6197817B1

  公开（公告）日：2001-03-06
• [EN] PHENYLPROPIONIC ACIDS AND ESTER COMPOUNDS AND METHODS FOR INDUCING BETA-BLOCKADE<br/>[FR] COMPOSES A BASE D'ACIDES ET D'ESTERS PHENYLPROPIONIQUES ET METHODES PERMETTANT DE PROVOQUER DES BETA-BLOCKAGES
  申请人：SELECTUS PHARMACEUTICALS INC

  公开号：WO2000042999A1

  公开（公告）日：2000-07-27

  Disclosed are compounds of formula (I) wherein R represents hydrogen or is a C-3 to C-6 cycloalkyl or C-4 to C-10 straight or branched carbon chain alkyl-cycloalkyl or a group -B-D, where B is C-2 to C-10 straight or branched carbon chain alkyl and D is hydroxy or alkyloxy or 2,3-dihydroxypropyl or 2,3-dialkyloxypropyl or 2,2-dialkyl-1,3-dioxolane-5-methyl, where alkyl is C-1 to C-10 straight or branched carbon chain; W represents CH(CH3)CH2-, C(CH3)2CH2-; Z represents hydrogen, -NHCOR2, -NHCONR2R3 or -NHSO2R2 or -NHSO2NR2R3 or -NHCOOR4 wherein R4 is alkyl of from 1 to about 6 carbon atoms, alkoxyalkyl wherein the alkyl groups may be the same or different and contain from 1 to about 6 carbon atoms, alkoxyaryl, cycloalkyl of from 3 to about 8 carbon atoms. R2 and R3 may be the same or different and represent hydrogen, alkyl of from 1 to about 6 carbon atoms, alkoxyalkyl wherein the alkyl groups may be the same or different and contain from 1 to about 6 carbon atoms, alkoxyaryl, cycloalkyl of from 3 to about 8 carbon atoms, a phenyl group substituted or unsubstituted, heteroaryl, furanyl, thiophenyl, imidazolyl, oxazolyl or indolyl or tetrahydrofuranyl, tetrahydropyranyl, dioxanyl, 2,2-dimethyl dioxolane-5-methyl, pyrrolidinyl, piperazinyl and tetrahydrooxazolyl, aralkyl except that R2 and R3 are not hydrogen when Z is -NHSO2R2, or R2 and R3 may together with N form a 5 to 7 membered heterocyclic group; and pharmaceutically acceptable salts thereof; and all stereoisomeric forms, as well as racemic mixtures. The compounds in the present invention relates to compounds, methods, formulation and pharmaceutical compositions for the general treatment or prophylaxis of diseases states which are responsive to attenuation of sympathetic nervous system activity or beta adrenergic blockade namely: coronary artery disease including myocardial ischemic disorders, angina and myocardial infarction; arrhythmia; hypertension; anxiety including panic attack; migraine or glaucoma by the intravenous or sublingual or oral or topical ocular administration.